INFLARX N.V.
INFLARX N.V.
Action · NL0012661870 · IFRX · A2H7A5 (XNAS)
Aperçu Indicateurs financiers
0,84 USD
1,19 % 0,010 USD
NASDAQ (XNAS) · Cours et graphiques actuels sur MoneyPeak
09.06.2025 21:20

Cours actuels de INFLARX N.V.

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
IFRX
USD
09.06.2025 21:20
0,84 USD
0,83 USD
+0,71 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 1,27 % -46,84 % -30,86 % -66,93 % -47,83 % -88,68 %
Allocation d'actifs
ActifPart %
Stock non-US49,50 %
Stock US49,12 %
Cash1,38 %
NotClassified0,00 %
Other0,00 %
Bond0,00 %
Les plus grandes positions
SymboleISINNomPart %
CRLCharles River Laboratories International Inc 6,62 %
TPLTexas Pacific Land Corporation 5,65 %
FNVFranco-Nevada Corporation 4,85 %
PSKPrairieSky Royalty Ltd 4,63 %
DB1Deutsche Börse AG 4,45 %
ASXASX Limited 4,41 %
ICEIntercontinental Exchange Inc 4,25 %
WPMWheaton Precious Metals Corp 4,08 %
ADMArcher-Daniels-Midland Company 3,93 %
MMCMarsh & McLennan Companies Inc 3,43 %
Répartition par régions
RégionPart %
North America81,33 %
Europe Developed7,36 %
Australasia5,98 %
Asia Developed4,25 %
Japan1,08 %
Africa/Middle East0,00 %
Asia Emerging0,00 %
Europe Emerging0,00 %
Latin America0,00 %
United Kingdom0,00 %
Répartition par secteurs
SecteurPart %
Finanzdienstleistungen33,23 %
Grundstoffe22,05 %
Energie18,96 %
Gesundheitswesen8,10 %
Immobilien7,47 %
Basiskonsumgüter5,46 %
Industrieunternehmen2,44 %
Technologie2,30 %
Verbrauchsgüter0,00 %
Telekommunikation0,00 %

Profil de l'entreprise pour INFLARX N.V. Action

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Données de base du fonds
Émetteur Horizon Kinetics
Type de titre ETF
Nom Horizon Kinetics Inflation Beneficiaries ETF
Devise du fonds USD
Catégorie World Large-Stock Growth
fund.
Chiffres clés du fonds
Taille du fonds 631.168,26 EUR
Stratégie d'investissement
The investment seeks long-term growth of capital in real (inflation-adjusted) terms. The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in the equity securities of domestic and foreign companies that are expected to benefit, either directly or indirectly, from rising prices (inflation). The fund's investments in equity securities are generally expected to include common stock, ownership units of publicly traded MLPs, and units of royalty trusts. The fund is non-diversified.

Données de l'entreprise

Nom INFLARX N.V.
Société InflaRx N.V.
Symbole IFRX
Site web https://www.inflarx.de
Marché d'origine XNAS NASDAQ
WKN A2H7A5
ISIN NL0012661870
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Niels C. Riedemann M.D., Ph.D.
Capitalisation boursière 70 Mio
Pays Allemagne
Devise USD
Employés 0,1 T
Adresse Winzerlaer Str. 2, 07745 Jena
Date d'introduction en bourse 2017-11-07

Symboles boursiers

Nom Symbole
Frankfurt IF0.F
NASDAQ IFRX

Autres actions

Les investisseurs qui détiennent INFLARX N.V. ont également les actions suivantes dans leur portefeuille :
ALTRIA GRP 19/29
ALTRIA GRP 19/29 Obligation
BAIDU INC - ADR
BAIDU INC - ADR Action
BIONTECH SE ADR
BIONTECH SE ADR Action
BYD
BYD Action
DT. BAHN FIN. 23/38 MTN
DT. BAHN FIN. 23/38 MTN Obligation
GAZPROM ADR
GAZPROM ADR Certificat de dépôt
GLOBAL FASHION GRP EO-,01
GLOBAL FASHION GRP EO-,01 Action
META PLATFORMS INC
META PLATFORMS INC Action
MICROSOFT CORP
MICROSOFT CORP Action
OPTION CARE HEALTH INC
OPTION CARE HEALTH INC Action
RIO TINTO
RIO TINTO Action
SQUARE INC A
SQUARE INC A Action
VA-Q-TEC AG
VA-Q-TEC AG Action
WEICHAI POWER CO
WEICHAI POWER CO Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025